here is a bit more to consider in regard to ACL's future: Taken...

here is a bit more to consider in regard to ACL's future:
Taken from May 2012 Open Briefing (Pete Smith):

http://openbriefing.com.au/OB/Alche...Phase-III-Trial-and-Company-Outlook-/681.aspx

"We want to keep our optionality on HA-Irinotecan.  If a company wanted to acquire our oncology assets, we’re in a much better position if we own them 100 percent.  If the Phase III trial is successful, the scalability of the technology will be understood by potential partners and we’re likely to have a lot of interest in the broader platform as well as HA-Irinotecan.
Once the platform is proven, we’ll have a host of different commercialisation and partnering opportunities.  We’ve focused on making generic drugs work better and creating new branded products but there are also opportunities for drug life cycle management.  For example, if a company has a drug that’s close to patent expiry, we could help it develop an improved version to maintain the franchise.  The technology could also help companies with drugs in development increase the chance of success by reducing the toxicity of the drug by enabling the use of a lower dose or maximising its efficacy."